Partnership announced
Body
On Jan. 13, the University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of highgrade non-muscle invasive bladder cancer (HG-NMIBC).